Contraceptive shortage blamed on takeover; WHO struggles to form fakes-policy group;

> Contraceptives maker MSD, the U.K. arm of Merck, has reportedly blamed the shortage of its Cerazette, Marvelon and Mercilon brands on its takeover of rival Schering-Plough in 2009. Article

> A working group mandated last May by WHO to address problems with counterfeits policy remains unformed just four months before it is due to report to members. Article

> Perrigo will acquire generics-maker Paddock Laboratories for $540 million. Release

> Boehringer Ingelheim will take over Amgen's 100,000-square-foot manufacturing facility with pilot plant and process development labs in Fremont, CA. Release

> Molecular Profiles is expanding its manufacturing services to encompass preformulation through  Phase 2a trials. Item

> Rentschler Biotechnologie is expected to assume manufacturing responsibility for lung injury treatment Traumakine and a proprietary bulk drug product. Item

> Cambrex has received manufacturing approval from the Danish Medicines Agency for its plan t in Hyderabad, India. Release

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.